Biopharmaceutical company Gilead Sciences to buy clinical-stage immuno-oncology company, Forty Seven, for $4.9B.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline”
Daniel O’Day, Gilead Chairman and CEO
Forty Seven has investigational Immuno-Oncology therapies in multiple clinical studies. Their leading product candidate is Magrolimab, a treatment for several cancers that targets the “do not eat me” signal that allows cancer cells to avoid destruction and permits a patients own immune system to eradicate those cancer cells.